{"filing":{"accession_number":"0001730430-26-000025","cik":"0001730430","ticker":"KNSA","company_name":"Kiniksa Pharmaceuticals International, plc","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"knsa-20260521x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1730430/000173043026000025/knsa-20260521x8k.htm"},"events":[{"id":9179,"run_id":8054,"accession_number":"0001730430-26-000025","anchor_item_number":"1.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The Company entered into a deed of waiver with Baker Bros. Advisors LP restricting the Shareholders' ability to convert Class A1/B1 shares into Class A/B shares if doing so would result in beneficial ownership exceeding 49.9% of voting rights. While this is a material definitive agreement affecting shareholder rights and voting control, it does not fit cleanly into the M\u0026A activity category (no acquisition, disposition, merger, or change of control is occurring) and is better classified as a structural governance arrangement that would affect investor assessment of control and dilution risk.","company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1694,"accession_number":"0001730430-26-000025","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The Company entered into a deed of waiver with Baker Bros. Advisors LP restricting the Shareholders' ability to convert Class A1/B1 shares into Class A/B shares if doing so would result in beneficial ownership exceeding 49.9% of voting rights. While this is a material definitive agreement affecting shareholder rights and voting control, it does not fit cleanly into the M\u0026A activity category (no acquisition, disposition, merger, or change of control is occurring) and is better classified as a structural governance arrangement that would affect investor assessment of control and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:37:21.707730+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1694,"accession_number":"0001730430-26-000025","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The Company entered into a deed of waiver with Baker Bros. Advisors LP restricting the Shareholders' ability to convert Class A1/B1 shares into Class A/B shares if doing so would result in beneficial ownership exceeding 49.9% of voting rights. While this is a material definitive agreement affecting shareholder rights and voting control, it does not fit cleanly into the M\u0026A activity category (no acquisition, disposition, merger, or change of control is occurring) and is better classified as a structural governance arrangement that would affect investor assessment of control and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:37:21.707730+00:00","company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","filing_date":"2026-05-26"}]}